Parties have the option to register descriptions which can appear on the ballot paper, instead of the party name. As the registrar for political parties, electoral law requires the Commission to assess whether a party\u2019s description meets the requirements set out in law. If it does not, the description cannot be registered.<\/p>
If a person, other than the candidate, is named in a description and thus appeared on the ballot paper, it is likely to mislead a voter about the candidate standing in their area. It would not therefore meet the legal requirements for a description, and the Commission would be required to refuse it.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4436", "label" : {"_value" : "Biography information for Cat Smith"} } , "answeringMemberConstituency" : {"_value" : "Lancaster and Fleetwood"} , "answeringMemberPrinted" : {"_value" : "Cat Smith"} , "dateOfAnswer" : {"_value" : "2024-05-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-13T09:41:23.637Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "36"} , "answeringDeptShortName" : {"_value" : "Speaker's Committee on the Electoral Commission"} , "answeringDeptSortName" : {"_value" : "Speaker's Committee on the Electoral Commission"} , "date" : {"_value" : "2024-05-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Political Parties: Registration"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the hon. Member for Lancaster and Fleetwood, representing the Speaker's Committee on the Electoral Commission, if she will hold discussions with the Electoral Commission on the reasons for which it rejected the application from (a) Kingston Independent Residents Group and (b) Workers Party Britain on registering a description that included the leaders of those parties.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/609", "label" : {"_value" : "Biography information for George Galloway"} } , "tablingMemberConstituency" : {"_value" : "Rochdale"} , "tablingMemberPrinted" : [{"_value" : "George Galloway"} ], "uin" : "25444"} , {"_about" : "http://data.parliament.uk/resources/1716362", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1716362/answer", "answerText" : {"_value" : "
Since the initial announcements regarding funding for National Health Service trusts to integrate artificial intelligence into lung cancer imaging, adjustments have been made to the list of participants. Three trusts have withdrawn from the initiative, and five additional trusts have been onboarded, due to the inclusion of a new imaging network. As a result, as set out in the answer of 7 May 2024, there are now 66 trusts across 12 imaging networks that are participating in this initiative.<\/p>
In the answer of 7 May 2024, 63 out of 66 trusts, in 11 of 12 imaging networks, had received funding. It is now confirmed that all 66 trusts in the 12 imaging networks participating have received or are in the process of receiving funding. These trusts are currently implementing artificial intelligence technologies to enhance diagnostic capabilities in lung cancer, consistent with the Government's commitment to advancing healthcare technology across the NHS.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-13T08:24:50.047Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lung Cancer: Artificial Intelligence"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 May 2024 to Question 24269 on Lung Cancer: Artificial Intelligence, which (a) NHS trusts have and (b) imaging network has not received funding.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4505", "label" : {"_value" : "Biography information for Peter Kyle"} } , "tablingMemberConstituency" : {"_value" : "Hove"} , "tablingMemberPrinted" : [{"_value" : "Peter Kyle"} ], "uin" : "25291"} , {"_about" : "http://data.parliament.uk/resources/1716411", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1716411/answer", "answerText" : {"_value" : "
The Home Office does not comment on the information requested due to the sensitivity of the agreement and the payments.<\/p>
<\/p>
The Home Office continues to work collaboratively with our French counterparts in relation to preventing illegal migration and therefore respects agreements made regarding transparency data.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4497", "label" : {"_value" : "Biography information for Michael Tomlinson"} } , "answeringMemberConstituency" : {"_value" : "Mid Dorset and North Poole"} , "answeringMemberPrinted" : {"_value" : "Michael Tomlinson"} , "dateOfAnswer" : {"_value" : "2024-05-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-13T10:46:06.467Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "1"} , "answeringDeptShortName" : {"_value" : "Home Office"} , "answeringDeptSortName" : {"_value" : "Home Office"} , "date" : {"_value" : "2024-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Undocumented Migrants: France"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for the Home Department, pursuant to the Answer of 7 May 2024 to Question 24423 on Undocumented Migrants: France, whether the payments made by his Department to the French authorities for their part in delivering the UK-France Joint Leader's Declaration are published as part of his Department's monthly transparency data on spending over £25,000.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1536", "label" : {"_value" : "Biography information for Emily Thornberry"} } , "tablingMemberConstituency" : {"_value" : "Islington South and Finsbury"} , "tablingMemberPrinted" : [{"_value" : "Emily Thornberry"} ], "uin" : "25189"} , {"_about" : "http://data.parliament.uk/resources/1716421", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1716421/answer", "answerText" : {"_value" : "
Department ministers and officials regularly meet with a range of organisations, with an interest in securing patient access to new cancer medicines. The National Institute for Health and Care Excellence (NICE) is the body that develops authoritative, evidence-based guidance for the National Health Service on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits, including medicines for myeloma. The NICE aims to publish guidance on all new medicines close to the point of licensing wherever possible, and has recommended many cancer medicines for NHS use that are now available to NHS patients, including through the Cancer Drugs Fund.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-13T08:43:01.5Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions she (a) has had and (b) plans to have with (i) charities and (ii) other organisations working to secure UK access to new drugs for (A) incurable, (B) relapsing and (C) remitting cancers such as myeloma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4370", "label" : {"_value" : "Biography information for Jess Phillips"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Yardley"} , "tablingMemberPrinted" : [{"_value" : "Jess Phillips"} ], "uin" : "25238"} , {"_about" : "http://data.parliament.uk/resources/1716422", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1716422/answer", "answerText" : {"_value" : "
The Department regularly meets with colleagues in the National Institute for Health and Care Excellence (NICE) to discuss a range of issues, including in relation to the NICE\u2019s methods for the evaluation of medicines. In 2022, the NICE introduced a number of changes to make its methods and processes fairer, faster, and more consistent. This includes the introduction of a broader severity modifier, in place of the end-of-life modifier. Since the changes were introduced, 79% of the NICE\u2019s appraisals of cancer medicines carried out under the updated methods have recommended the use of the treatment for some or all of the eligible patient population, either for routine use or use through the Cancer Drugs Fund. The approval rate for all cancer appraisals carried out since 2009, when the end-of-life modifier was introduced, is 78%.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-13T08:48:27.183Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cancer: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she (a) has had discussions and (b) plans to have discussions with the National Institute for Health and Care Excellence on (i) its use of the new severity modifier and (ii) how it (A) measures and (B) reports the impact of the modifier on approval of treatments for (1) cancers, (2) relapsing and remitting conditions and (3) conditions that are more prevalent in older people.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4370", "label" : {"_value" : "Biography information for Jess Phillips"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Yardley"} , "tablingMemberPrinted" : [{"_value" : "Jess Phillips"} ], "uin" : "25239"} , {"_about" : "http://data.parliament.uk/resources/1716429", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1716429/answer", "answerText" : {"_value" : "
The Home Office will not be providing a running commentary on ongoing operational activity. However, all individuals will have their cases considered in line with the published inadmissibility guidance:<\/p>